ArticleParkinsonism & related disorders2019
Multimodal neuroimaging relationships in progressive supranuclear palsy.
Article in Parkinsonism & related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Pooled it
- Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis.Journal of neurology · 2023Pooled it
- A technical review of canonical correlation analysis for neuroscience applications.Human brain mapping · 2020Pooled it
- Selective white matter tract vulnerability associated with tau burden in progressive supranuclear palsy and Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Brainstem and Cerebellar Volume Loss and Associated Clinical Features in Progressive Supranuclear Palsy.Annals of clinical and translational neurology · 2026Observational
- The Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research.Diseases (Basel, Switzerland) · 2025Review
- Brainstem and cerebellar radiological findings in progressive supranuclear palsy.Brain communications · 2025Review
- Multimodal neuroimaging to characterize symptom-specific networks in movement disorders.NPJ Parkinson's disease · 2024Review
- Multimodal cross-examination of progressive apraxia of speech by diffusion tensor imaging-based tractography and Tau-PET scans.Human brain mapping · 2024Article
- Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.Brain communications · 2024Article
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
- Pathomechanisms of depression in progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Pathomechanisms of cognitive impairment in progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies.Journal of neuropathology and experimental neurology · 2022Article
- Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies.Brain communications · 2022Article
- The Legacy of the TTASAAN Report - Premature Conclusions and Forgotten Promises About SPECT Neuroimaging: A Review of Policy and Practice Part II.Frontiers in neurology · 2022Article
- Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.Nature reviews. Neurology · 2021Review
- Neuroinflammation predicts disease progression in progressive supranuclear palsy.Journal of neurology, neurosurgery, and psychiatry · 2021Article
- IntegratedFrontiers in aging neuroscience · 2021Article
- Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy.NeuroImage. Clinical · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Progressive supranuclear palsy is characterized primarily by 4R tau inclusions, atrophy in the brainstem and basal ganglia, and neurodegeneration along the dentatorubrothalamic tract, which are measurable in vivo using flortaucipir PET, T1-weighted MRI, and MRI with diffusion tensor imaging (DTI). However, little is known about how these processes relate to each other. The aim of this study was to investigate multimodal associations between flortaucipir PET uptake, tissue volume loss on structural MRI and white matter tract disruption on DTI. Thirty-four patients with progressive supranuclear palsy and 29 normal controls underwent flortaucipir PET, MRI and DTI. Voxel-wise comparison was performed between patients and controls. Sparse canonical correlations analysis was applied on regional measurements of flortaucipir uptake, tissue volume, fractional anisotropy and mean diffusivity of the PSP population. Pearson's correlation coefficients were assessed across modalities on the regions identified by the sparse canonical correlation analyses. Sparse canonical correlation analyses identified associations between elevated flortaucipir uptake in the cerebellar dentate, red nucleus and subthalamic nucleus and decreased volume in the same regions, and decreased fractional anisotropy and increased mean diffusivity in tracts including the superior cerebellar peduncle, sagittal striatum and posterior corona radiata. Furthermore, decreased fractional anisotropy and increased mean diffusivity in the body of the corpus callosum and anterior and superior corona radiata were related to volume loss in the frontal lobe. Tau uptake measured by flortaucipir PET appears to be related to the neurodegenerative process of progressive supranuclear palsy, including reduced tissue volume and white matter tract degeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.